Status
Conditions
Treatments
About
The goal of the KiTaLymph trial is to investigate whether the application of kinesio tape is effective in women with persistent (>6 months) breast and/or trunk oedema after treatment for breast cancer.
The main objectives are to assess whether kinesio taping:
This study will compare a control group receiving standard care-decongestive lymphatic therapy (DLT)-to an intervention group receiving DLT in combination with Kinesio taping, in order to determine whether the addition of Kinesio tape yields superior clinical outcomes.
Participants will be randomly allocated to one of the two study arms. Both groups will participate in a 4-week intervention phase, consisting of two treatment sessions per week. This will be followed by a 6-month follow-up period to assess the durability of treatment effects and cost-related outcomes.
A total of approximately 128 participants will be recruited. Outcome assessments will be conducted at baseline, immediately post-intervention (1 month), and at 3 and 6 months following the conclusion of the intervention. These assessments will include standardized patient-reported outcome measures evaluating symptoms, quality of life, and pain-namely, the Breast Edema Questionnaire (BrEQ), the EORTC QLQ-BR23, the EQ-5D-5L, and a visual analogue scale (VAS)-as well as objective physical measurements of oedema using the LymphScanner (expressed as percentage water content, PWC%).
In addition to the primary research objective, several ancillary sub-studies will be conducted. These will include: (1) a longitudinal analysis of the effects of standard treatment over time; (2) an evaluation of the responsiveness and clinical utility of the BrEQ; and (3) a cross-sectional investigation of the compression pressure exerted by various compression bras. All sub-studies are methodologically feasible within the projected sample size of the primary trial and aim to provide supplementary insights into the clinical management of breast and truncal oedema.
Full description
As outlined in the brief summary, three substudies will be embedded within the main study sample. The following section provides a concise overview of the methodological approach for each of these substudies.
The longitudinal effectof Decongestive Lymphatic Therapy:
This substudy examines the (long-term) effect of standard decongestive lymphatic therapy (DLT) on symptoms and functioning in women with persistent breast and/or trunk oedema following breast cancer treatment. The analysis will focus on participants in the control group, who receive DLT alone. Outcomes such as symptom burden (BrEQ), local tissue water (PWC%), pain (VAS), and quality of life (EQ-5D-5L and EORTC QLQ-BR23) will be tracked at multiple time points: baseline, after 1 month of intervention, and 3 and 6 months post-end of intervention.
No additional intervention is introduced beyond the standard treatment already described in the main study protocol. The substudy will assess the sustainability of symptom improvement over time and provide insight into the standalone effectiveness of DLT.
Responsiveness of the Breast Edema Questionnaire:
This substudy aims to evaluate the responsiveness of the BrEQ, a validated questionnaire used to assess symptoms related to breast oedema. Although the BrEQ has demonstrated strong psychometric properties, its ability to detect clinically meaningful changes over time has not yet been investigated.
Participants from both groups in the main study can participate in this sub-study. The design follows a longitudinal cohort structure integrated into the RCT, without any additional intervention. Two subgroups will be analysed: (1) the intensive phase group (from baseline to one month after the intervention), in which clinical improvement is expected, and (2) the maintenance phase group (from three to four months after the intervention), in which symptom levels are expected to remain stable.
In both groups, BrEQ scores will be compared with patient-reported change using the Global Perceived Effect (GPE) scale. Responsiveness will be quantified through Receiver Operating Characteristic (ROC) curve analysis, and effect size calculations (Cohen's d, Standardized Response Mean). This substudy requires no additional intervention and uses existing follow-up time points supplemented by one extra BrEQ and GPE assessment at four months post-end of intervention.
Pressure and comfort of compression bras:
This substudy investigates the pressure exerted by different commercially available compression bras and evaluates patient-reported comfort. The goal is to assess whether these garments provide adequate therapeutic compression and are acceptable for daily use.
The design follows a cross-sectional approach conducted in a subset of participants (5 participants/cup size) who consent to this additional component. Each participating patient will receive different compression bras, worn for one week each.
Pressure beneath the garment will be measured using the PicoPress device (Microlab, Italy) on the first day of wear. After each one-week wear period, participants will complete an adapted version of the ICC Compression Questionnaire (ICC-CQ) to assess comfort and usability.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Female patients previously treated for breast cancer.
Suffering from persistent (>6 months) breast and/or trunk oedema, established at least six months after completion of radiotherapy.
Objective measurement:
BrEQ score ≥9.
PWC% (LymphScanner) showing at least one of the following:
Clinical evaluation:
At least one positive sign of breast and/or flank oedema such as:
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
128 participants in 2 patient groups
Loading...
Central trial contact
Nick Gebruers, Associate Professor; Tessa De Vrieze, Phd pt postdoctoral fellow
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal